Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications
- Thursday, January 6, 2022, 7:13
- PR Newswire
- Add a comment
INDIANAPOLIS and EDMONTON, AB, Jan. 6, 2022 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) has acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central and…
About the Author
admin has written 21793 stories on this site.